RU-1205
Synthetic nonsteroidal estrogen
| RU-1205 | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
RU-1205 is a synthetic, nonsteroidal estrogen of the stilbestrol group that was developed in the 1960s. It is structurally related to diethylstilbestrol (DES), a well-known synthetic estrogen.
Chemical structure and properties[edit]
RU-1205 is a member of the stilbestrol family, characterized by its nonsteroidal structure. The compound is defined by its chemical formula, which includes a phenolic hydroxyl group and a dimethylaminoethoxy side chain. This structure is similar to that of other synthetic estrogens, which allows it to bind to estrogen receptors in the body.
Pharmacology[edit]
As an estrogen, RU-1205 interacts with estrogen receptors, which are part of the nuclear receptor family of intracellular receptors. These receptors, when activated by binding to an estrogen, can influence the expression of specific genes, leading to the physiological effects associated with estrogenic activity. The precise binding affinity and activity of RU-1205 compared to other estrogens like DES or natural estrogens such as estradiol are subjects of pharmacological interest.
Potential applications[edit]
RU-1205, like other synthetic estrogens, was initially investigated for its potential use in hormone replacement therapy and other estrogen-related treatments. However, due to the adverse effects associated with synthetic estrogens, particularly those related to DES, the clinical use of RU-1205 has been limited.
Safety and side effects[edit]
The safety profile of RU-1205 has not been extensively documented in the literature. However, it is known that synthetic estrogens can have significant side effects, including an increased risk of thromboembolism, breast cancer, and endometrial cancer. These risks have led to a decline in the use of nonsteroidal synthetic estrogens in clinical practice.
Related compounds[edit]
RU-1205 is related to other synthetic estrogens such as diethylstilbestrol and hexestrol. These compounds share a similar mechanism of action but differ in their pharmacokinetic properties and side effect profiles.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
